Prokidney (PROK) Common Equity (2021 - 2026)

Prokidney (PROK) has 6 years of Common Equity data on file, last reported at -$1.0 billion in Q1 2026.

• Common Equity for Q1 2026 came in at -$1.0 billion, down 2.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 2.53% YoY), and the FY2025 annual result was -$1.0 billion, down 1.63% from the prior year.
• Common Equity retreated to -$1.0 billion in Q1 2026 per PROK's latest filing, from -$1.0 billion in the prior quarter.
• Over five years, Common Equity peaked at $20.2 million in Q1 2022 and troughed at -$1.6 billion in Q1 2023.
• A 5-year average of -$963.1 million and a median of -$1.0 billion in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity soared 101661.03% in 2022, then sank 20327.23% in 2023.
• A 5-year view of Common Equity shows it stood at -$1.1 billion in 2022, then decreased by 0.62% to -$1.1 billion in 2023, then climbed by 9.83% to -$995.0 million in 2024, then retreated by 1.63% to -$1.0 billion in 2025, then retreated by 1.24% to -$1.0 billion in 2026.
• Business Quant data shows PROK's Common Equity at -$1.0 billion in Q1 2026, -$1.0 billion in Q4 2025, and -$1.0 billion in Q3 2025.